Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


27.03.2017

2 Am J Surg
2 Ann Oncol
2 Ann Surg Oncol
4 Anticancer Res
3 BMC Cancer
1 Br J Cancer
1 Breast Cancer
3 Breast Cancer (Dove Med Press)
1 Breast Cancer Res
10 Breast Cancer Res Treat
2 Breast J
3 Cancer
1 Cancer Epidemiol Biomarkers Prev
1 Cancer Res
1 Carcinogenesis
1 Clin Breast Cancer
1 Genes Chromosomes Cancer
1 J Clin Oncol
1 J Surg Oncol
1 Lancet Oncol
2 Oncogene
2 Oncol Rep
1 Oncology
5 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Surg

  1. LUDWIG KK, Neuner J, Butler A, Geurts JL, et al
    Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review.
    Am J Surg. 2016;212:660-669.
    PubMed     Text format     Abstract available

  2. PETTKE E, Ilonzo N, Ayewah M, Tsantes S, et al
    Short-term, postoperative breast cancer outcomes in patients with advanced age.
    Am J Surg. 2016;212:677-681.
    PubMed     Text format     Abstract available


    Ann Oncol

  3. LESURF R, Griffith OL, Griffith M, Hundal J, et al
    Genomic characterisation of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy - results from the ACOSOG Z1041 (Alliance) trial.
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available

  4. CARDOSO F, Costa A, Senkus E, Aapro M, et al
    3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
    Ann Oncol. 2017 Feb 19. doi: 10.1093.
    PubMed     Text format    


    Ann Surg Oncol

  5. TRAVIS CLIFTON G, Litton JK, Arrington K, Ponniah S, et al
    Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients.
    Ann Surg Oncol. 2017 Mar 17. doi: 10.1245/s10434-017-5844.
    PubMed     Text format     Abstract available

  6. MORROW M, Hawley ST, McLeod MC, Hamilton AS, et al
    Surgeon Attitudes and Use of MRI in Patients Newly Diagnosed with Breast Cancer.
    Ann Surg Oncol. 2017 Mar 22. doi: 10.1245/s10434-017-5840.
    PubMed     Text format     Abstract available


    Anticancer Res

  7. MACK N, Mazzio EA, Bauer D, Flores-Rozas H, et al
    Stable shRNA Silencing of Lactate Dehydrogenase A (LDHA) in Human MDA-MB-231 Breast Cancer Cells Fails to Alter Lactic Acid Production, Glycolytic Activity, ATP or Survival.
    Anticancer Res. 2017;37:1205-1212.
    PubMed     Text format     Abstract available

  8. WENDT C, Lindblom A, Arver B, VON Wachenfeldt A, et al
    Parent of Origin and Prognosis in Familial Breast Cancer in Sweden.
    Anticancer Res. 2017;37:1257-1262.
    PubMed     Text format     Abstract available

  9. DIERAS V, Pop S, Berger F, Dujaric ME, et al
    First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.
    Anticancer Res. 2017;37:1403-1407.
    PubMed     Text format     Abstract available

  10. KIM HA, Kim JH, Choi HS, Kim YG, et al
    Core Needle Biopsy Specimens Are More Appropriate than Surgical Specimens for Evaluating the Expression of Phosphoproteins as Biological Markers in Invasive Breast Cancer.
    Anticancer Res. 2017;37:1409-1412.
    PubMed     Text format     Abstract available


    BMC Cancer

  11. GARCIA-SAENZ JA, Ayllon P, Laig M, Acosta-Eyzaguirre D, et al
    Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging.
    BMC Cancer. 2017;17:210.
    PubMed     Text format     Abstract available

  12. PETERS IT, van der Steen MA, Huisman BW, Hilders CG, et al
    Morphological and phenotypical features of ovarian metastases in breast cancer patients.
    BMC Cancer. 2017;17:206.
    PubMed     Text format     Abstract available

  13. PADRO M, Louie RJ, Lananna BV, Krieg AJ, et al
    Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells.
    BMC Cancer. 2017;17:203.
    PubMed     Text format     Abstract available


    Br J Cancer

  14. ROUZIER R, Uzan C, Rousseau A, Guillot E, et al
    Multicenter prospective evaluation of the reliability of the combined use of two models to predict non-sentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: the MSKCC nomogram and the Tenon score. Results of the NO
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Breast Cancer

  15. LIN WZ, Xu QN, Wang HB, Li XY, et al
    Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials.
    Breast Cancer. 2017 Mar 21. doi: 10.1007/s12282-017-0770.
    PubMed     Text format     Abstract available


    Breast Cancer (Dove Med Press)

  16. BULUT A, Bulut A
    Knowledge, attitudes and behaviors of primary health care nurses and midwives in breast cancer early diagnosis applications.
    Breast Cancer (Dove Med Press). 2017;9:163-169.
    PubMed     Text format     Abstract available

  17. KISPERT S, McHowat J
    Recent insights into cigarette smoking as a lifestyle risk factor for breast cancer.
    Breast Cancer (Dove Med Press). 2017;9:127-132.
    PubMed     Text format     Abstract available

  18. HALLMAN K, Aleck K, Dwyer B, Lloyd V, et al
    The effects of turmeric (curcumin) on tumor suppressor protein (p53) and estrogen receptor (ERalpha) in breast cancer cells.
    Breast Cancer (Dove Med Press). 2017;9:153-161.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  19. PAQUET ER, Lesurf R, Tofigh A, Dumeaux V, et al
    Detecting gene signature activation in breast cancer in an absolute, single-patient manner.
    Breast Cancer Res. 2017;19:32.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  20. MUTI P, Secreto G, Krogh V
    Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
    Breast Cancer Res Treat. 2017 Mar 18. doi: 10.1007/s10549-017-4194.
    PubMed     Text format    

  21. STREKALOVA E, Malin D, Rajanala H, Cryns VL, et al
    Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4201.
    PubMed     Text format     Abstract available

  22. BASELGA J, Morales SM, Awada A, Blum JL, et al
    A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4199.
    PubMed     Text format     Abstract available

  23. KIM GM, Kim S, Park HS, Kim JY, et al
    Chemotherapy-induced irreversible alopecia in early breast cancer patients.
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4204.
    PubMed     Text format     Abstract available

  24. JENDRIAN S, Steffens K, Schmalfeldt B, Laakmann E, et al
    Quality of life in patients with recurrent breast cancer after second breast-conserving therapy in comparison with mastectomy: the German experience.
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4208.
    PubMed     Text format     Abstract available

  25. TRYFONIDIS K, Marreaud S, Khaled H, De Valk B, et al
    Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4203.
    PubMed     Text format     Abstract available

  26. MATTER-WALSTRA K, Schwenkglenks M, Dedes KJ
    Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4209.
    PubMed     Text format    

  27. LIM YJ, Lee SW, Choi N, Kwon J, et al
    Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice.
    Breast Cancer Res Treat. 2017 Mar 17. doi: 10.1007/s10549-017-4206.
    PubMed     Text format     Abstract available

  28. BOURKE M, Soden D, Clover AJ
    Effective treatment of intractable cutaneous metastases of breast cancer with electrochemotherapy: a useful contributor to cutaneous disease control.
    Breast Cancer Res Treat. 2017 Mar 17. doi: 10.1007/s10549-017-4187.
    PubMed     Text format    

  29. FURLANETTO J, Jackisch C, Untch M, Schneeweiss A, et al
    Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69).
    Breast Cancer Res Treat. 2017 Mar 17. doi: 10.1007/s10549-017-4200.
    PubMed     Text format     Abstract available


    Breast J

  30. OMARINI C, Filieri ME, Depenni R, Grizzi G, et al
    Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid.
    Breast J. 2017 Mar 22. doi: 10.1111/tbj.12808.
    PubMed     Text format    

  31. ACKERMAN MG, Shapiro PA, Coe A, Trivedi MS, et al
    The Impact of Mental Illness on Uptake of Genetic Counseling for Hereditary Breast Cancer and Ovarian Cancer in a Multiethnic Cohort of Breast Cancer Patients.
    Breast J. 2017 Mar 21. doi: 10.1111/tbj.12791.
    PubMed     Text format     Abstract available


    Cancer

  32. PRINTZCANCER C
    Study to examine genetic factors behind increased risk of breast cancer in African Americans.
    Cancer. 2017;123:1083-1084.
    PubMed     Text format    

  33. PRINTZCANCER C
    Breast cancer mortality rates decline internationally, with some major exceptions.
    Cancer. 2017;123:1085.
    PubMed     Text format    

  34. MAMTANI A, Patil S, Stempel MM, Morrow M, et al
    Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?
    Cancer. 2017 Mar 23. doi: 10.1002/cncr.30658.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  35. BEMANIAN A, Beyer KM
    Measures Matter: The Local Exposure/Isolation (LEx/Is) Metrics and Relationships between Local-Level Segregation and Breast Cancer Survival.
    Cancer Epidemiol Biomarkers Prev. 2017.
    PubMed     Text format     Abstract available


    Cancer Res

  36. LIAO L, Song M, Li X, Tang L, et al
    E3 ubiquitin ligase UBR5 drives the growth and metastasis of triple negative breast cancer.
    Cancer Res. 2017 Mar 22. pii: canres.2409.2016.
    PubMed     Text format     Abstract available


    Carcinogenesis

  37. LI J, Wang Y, Zhu Y, Gong Y, et al
    Breast cancer risk-associated variants at 6q25.1 influence risk of hepatocellular carcinoma in a Chinese population.
    Carcinogenesis. 2017 Mar 3. doi: 10.1093.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  38. REZENDE LM, Marson FA, Lima CS, Bertuzzo CS, et al
    Can MTHFR C677T and A1298C Polymorphisms Alter the Risk and Severity of Sporadic Breast Cancer in Brazilian Women?
    Clin Breast Cancer. 2017 Feb 16. pii: S1526-8209(16)30341.
    PubMed     Text format     Abstract available


    Genes Chromosomes Cancer

  39. FEJZO MS, Anderson L, Chen HW, Guandique E, et al
    Proteasome Ubiquitin Receptor PSMD4 is an Amplification Target in Breast Cancer and May Predict Sensitivity to PARPi.
    Genes Chromosomes Cancer. 2017 Mar 18. doi: 10.1002/gcc.22459.
    PubMed     Text format     Abstract available


    J Clin Oncol

  40. TAYLOR C, Correa C, Duane FK, Aznar MC, et al
    Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.
    J Clin Oncol. 2017 Mar 20:JCO2016720722. doi: 10.1200/JCO.2016.72.0722.
    PubMed     Text format     Abstract available


    J Surg Oncol

  41. NING K, Wang T, Sun X, Zhang P, et al
    UCH-L1-containing exosomes mediate chemotherapeutic resistance transfer in breast cancer.
    J Surg Oncol. 2017 Mar 23. doi: 10.1002/jso.24614.
    PubMed     Text format     Abstract available


    Lancet Oncol

  42. RUGO HS, Seneviratne L, Beck JT, Glaspy JA, et al
    Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
    Lancet Oncol. 2017 Mar 14. pii: S1470-2045(17)30109.
    PubMed     Text format     Abstract available


    Oncogene

  43. FOO TK, Tischkowitz M, Simhadri S, Boshari T, et al
    Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available

  44. THEWES V, Simon R, Hlevnjak M, Schlotter M, et al
    The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERalpha-negative breast cancer.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    Oncol Rep

  45. GIRGERT R, Emons G, Grundker C
    17beta-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinib.
    Oncol Rep. 2017;37:1212-1218.
    PubMed     Text format     Abstract available

  46. MAO X, Qiao Z, Fan C, Guo A, et al
    Expression pattern and methylation of estrogen receptor alpha in breast intraductal proliferative lesions.
    Oncol Rep. 2016;36:1868-74.
    PubMed     Text format     Abstract available


    Oncology

  47. STUBER T, Novopashenny I, Diessner J, Bartmann C, et al
    Are There Breast Cancer Patients with Node-Negative Small Tumours, Who Do Not Benefit from Adjuvant Systemic Therapy?
    Oncology. 2017 Mar 24. doi: 10.1159/000455050.
    PubMed     Text format     Abstract available


    PLoS One

  48. SHEN CJ, Kuo YL, Chen CC, Chen MJ, et al
    MMP1 expression is activated by Slug and enhances multi-drug resistance (MDR) in breast cancer.
    PLoS One. 2017;12:e0174487.
    PubMed     Text format     Abstract available

  49. LEE J, Hong BS, Ryu HS, Lee HB, et al
    Transition into inflammatory cancer-associated adipocytes in breast cancer microenvironment requires microRNA regulatory mechanism.
    PLoS One. 2017;12:e0174126.
    PubMed     Text format     Abstract available

  50. CHANG YW, Singh KP
    Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells.
    PLoS One. 2017;12:e0174227.
    PubMed     Text format     Abstract available

  51. HAN J, Lee HB, Lee ES, Kang YJ, et al
    The treatment outcomes and the use of adjuvant therapies in breast cancer patients with severe co-morbidities.
    PLoS One. 2017;12:e0173721.
    PubMed     Text format     Abstract available

  52. ZHANG N, Fielding R, Soong I, Chan KK, et al
    Psychometric assessment of the Chinese version of the brief illness perception questionnaire in breast cancer survivors.
    PLoS One. 2017;12:e0174093.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: